Dexcom 发射Stelo号,这是美国第一个用于2型糖尿病和前糖尿病的 OTC CGM 。 Dexcom launches Stelo, the first OTC CGM in the US for type 2 diabetics and prediabetics.
Dexcom已推出Stelo, 这是美国第一个场外连续葡萄糖监测器(CGM), Dexcom has launched Stelo, the first over-the-counter continuous glucose monitor (CGM) in the US. Stelo为2型糖尿病患者设计,不使用胰岛素或前糖尿病,用户可以跟踪葡萄糖水平、饮食、锻炼、压力和其他因素,可以无处方购买。 Designed for people with type 2 diabetes not using insulin or prediabetics, Stelo allows users to track glucose levels, diet, exercise, stress and other factors, and is available for purchase without a prescription. Stelo 是一种戴在上臂上的 15 天可穿戴设备，可将数据发送到智能手机应用程序，以提醒用户血糖显着飙升。 Stelo is a 15-day wearable device worn on the upper arm, sending data to a smartphone app to alert users of significant glucose spikes. 该装置符合FSA和HSA的条件,可在线购买一个月的供应,每年99美元,或每月签署89美元的持续订阅。 The device is FSA and HSA eligible and can be bought for a one-month supply online for $99 or signed up for an ongoing subscription at $89 a month.